company background image
0VQ logo

PureTech Health DB:0VQ Stock Report

Last Price

€2.62

Market Cap

€709.7m

7D

-0.8%

1Y

-2.4%

Updated

16 Jun, 2024

Data

Company Financials +

0VQ Stock Overview

Engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.

0VQ fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

PureTech Health plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PureTech Health
Historical stock prices
Current Share PriceUK£2.62
52 Week HighUK£2.82
52 Week LowUK£1.60
Beta0.98
1 Month Change2.34%
3 Month Change15.93%
1 Year Change-2.42%
3 Year Change-36.41%
5 Year Changen/a
Change since IPO-15.07%

Recent News & Updates

Recent updates

Shareholder Returns

0VQDE BiotechsDE Market
7D-0.8%-2.7%-3.1%
1Y-2.4%-24.2%-0.5%

Return vs Industry: 0VQ exceeded the German Biotechs industry which returned -24.2% over the past year.

Return vs Market: 0VQ underperformed the German Market which returned -0.5% over the past year.

Price Volatility

Is 0VQ's price volatile compared to industry and market?
0VQ volatility
0VQ Average Weekly Movement7.8%
Biotechs Industry Average Movement4.2%
Market Average Movement5.0%
10% most volatile stocks in DE Market10.3%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 0VQ has not had significant price volatility in the past 3 months.

Volatility Over Time: 0VQ's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
201590Bharatt Chowrirawww.puretechhealth.com

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders.

PureTech Health plc Fundamentals Summary

How do PureTech Health's earnings and revenue compare to its market cap?
0VQ fundamental statistics
Market cap€709.73m
Earnings (TTM)-€61.38m
Revenue (TTM)€3.11m

228.1x

P/S Ratio

-11.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0VQ income statement (TTM)
RevenueUS$3.33m
Cost of RevenueUS$96.24m
Gross Profit-US$92.90m
Other Expenses-US$27.21m
Earnings-US$65.70m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.24
Gross Margin-2,789.94%
Net Profit Margin-1,972.88%
Debt/Equity Ratio24.8%

How did 0VQ perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.